Nuttasith Larpparisuth

Dr. Nuttasith Larpparisuth

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
Wisit CheungpasitpornWisit Cheungpasitporn
Wisit Cheungpasitporn
ALAdisorn Lumpaopong
Adisorn Lumpaopong
This is an Early Access article. Please select the PDF button, above, to view it.

1 October 2019 in Transplantation Proceedings
Verified
Journal Article
Closed access
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
SPSoontorn Pinpaiboon
Soontorn Pinpaiboon
NRNartsiri Ratchawang
Nartsiri Ratchawang
RPRatchawat Promraj
Ratchawat Promraj
PSPeenida Skulratanasak
Peenida Skulratanasak
NPNalinee Premasathian
Nalinee Premasathian

1 March 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
NPN. Premasathian
N. Premasathian
KVK. Vareesangthip
K. Vareesangthip
BCB. Cheunsuchon
B. Cheunsuchon
PPP. Parichatikanon
P. Parichatikanon
AVA. Vongwiwatana
A. Vongwiwatana

15 April 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PSPeenida Skulratanasak
Peenida Skulratanasak
TLThidarat Luxsananun
Thidarat Luxsananun
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
NPNalinee Premasathian
Nalinee Premasathian
AVAttapong Vongwiwatana
Attapong Vongwiwatana
Background: HLA-DQ antibodies are the most prevalent de novo donor-specific antibodies (dnDSAs) after kidney transplantation (KT). The immunogenicity and impact of each HLA-DQ mismatch on graft outcomes can vary considerably. Methods: This retrospective cohort study investigated the prevalence and risk factors for dnDSA development in patients who underwent KT at Siriraj Hospital between 2006 and 2020 and had HLA-DQB1 mismatches. Our center employed a protocol for post-KT dnDSA surveillance. The impact of dnDSAs on late rejection and graft survival was evaluated. Results: In our cohort of 491 KT recipients, 59 (12.02%) developed dnDSAs to HLA-DQB1 at a median time of 4.2 years after KT. The risk of dnDSA occurrence was significantly higher among recipients with HLA-DQ7 mismatch (HR: 2.8; 95% CI: 1.21–6.52; P = 0.017) and HLA-DQ9 mismatch (HR: 2.63; 95% CI: 1.11–6.27; P = 0.028). Recipients who developed dnDSAs were younger (P = 0.009), had higher rates of medication nonadherence (P = 0.031), had pre-KT panel reactive antibody levels above 20% (P = 0.044), and received non-tacrolimus immunosuppression (P < 0.001) compared to those without. Recipients who developed dnDSAs to HLA-DQ exhibited a significantly higher incidence of late graft rejection (HR: 7.76; 95% CI: 5–12.03; P < 0.0001) and inferior death-censored graft survival than those without dnDSAs (log rank P < 0.001). Conclusion: The patients with HLA-DQ7 and HLA-DQ9 mismatches exhibit the highest risk of developing dnDSAs. Individualized immunosuppression adjustment and kidney allocation based on specific HLA-DQ mismatch may enhance long-term graft survival.

11 October 2022 in Current Opinion in Nephrology and Hypertension
Verified
Journal Article
Closed access
PSPeenida Skulratanasak
Peenida Skulratanasak
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
Purpose of review: Lipid disorder is a prevalent complication in kidney transplant recipients (KTRs) resulting in cardiovascular disease (CVD), which influences on patient outcomes. Immunosuppressive therapy demonstrated the major detrimental effects on metabolic disturbances. This review will focus on the effect of immunosuppressive drugs, lipid-lowering agents with current management, and future perspectives for lipid management in KTRs. Recent findings: The main pathogenesis of hyperlipidemia indicates an increase in lipoprotein synthesis whilst the clearance of lipid pathways declines. Optimization of immunosuppression is a reasonable therapeutic strategy for lipid management regarding immunologic risk. Additionally, statin is the first-line lipid-lowering drug, followed by a combination with ezetimibe to achieve the low-density lipoprotein cholesterol (LDL-C) goal. However, drug interaction between statins and immunosuppressive medications should be considered because both are mainly metabolized through cytochrome P450 3A4. The prevalence of statin toxicity was significantly higher when concomitantly prescribed with cyclosporin, than with tacrolimus. Summary: To improve cardiovascular outcomes, LDL-C should be controlled at the target level. Initiation statin at a low dose and meticulous titration is crucial in KTRs. Novel therapy with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which is highly effective in reducing LDL-C and cardiovascular complications, and might prove to be promising therapy for KTRs with statin resistance or intolerance.

13 December 2021 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
NLNuttasith Larpparisuth
Nuttasith Larpparisuth
SNSupanit Nivatvongs
Supanit Nivatvongs
AIAtiporn Ingsathit
Atiporn Ingsathit
KNKajohnsak Noppakun
Kajohnsak Noppakun
ALAdisorn Lumpaopong
Adisorn Lumpaopong
NPNalinee Premasathian
Nalinee Premasathian